We have located links that may give you full text access.
English Abstract
Journal Article
Review
[Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma].
Nihon Rinsho. Japanese Journal of Clinical Medicine 2007 November
Patients with differentiated thyroid carcinoma are commonly treated long-term with thyrotropin (TSH)-suppressive thyroxine replacement therapy, which lead to a state of subclinical hyperthyroidism. Many studies including meta-analysis, there are increasing risk in the state of subclinical hyperthyroidism, especially in bone metabolism and cardiac dysfunction. Although there is a marked discrepancy in various therapeutic opinions between Japan and other countries, TSH suppressive therapy would be advisable to aim at TSH levels in the low normal range in low risk patients, whereas TSH levels should be suppressed in non-cured or high risk patients.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app